<DOC>
	<DOCNO>NCT02037074</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , sequential cohort , ascend oral dose study safety , tolerability , pharmacokinetics , pharmacodynamics EVP-6308 administer 14 day subject schizophrenia stable anti-psychotic regimen .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacokinetic ( PK ) Pharmacodynamic ( PD ) Effects EVP-6308 Potential EVP-6308 Affect PK Properties Antipsychotic Regimen Subjects With Schizophrenia Currently Receiving Stable Treatment With 2 Atypical Antipsychotics</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>â€¢ Diagnosed schizophrenia , male female subject , 18 60 year age Clinically significant abnormality physical examination , medical history , ECG , vital sign , laboratory value , unstable medical psychiatric illness Any disorder may interfere drug absorption Clinically significant allergy sensitivity medication Positive test human immunodeficiency virus ( HIV ) antibody , Hepatitis B surface antigen , Hepatitis C antibody Pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Phosphodiesterase 10 inhibitor</keyword>
</DOC>